Table 7:
Medication Monitoring*
| Methotrexate**# | Sulfasalazine** | Leflunomide# | Tocilizumab | Anakinra | Tofacitinib | Canakinumab | NSAIDs** | Hydroxychloroquine | TNFi | Abatacept | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CBC /diff and
LFTs -Baseline -1-2 months after starting -Every 3-4 months thereafter*** |
X | X | X | X | X | X | X | ||||
| CBC/diff and
LFTs -Baseline -Every 6-12 months |
X | ||||||||||
| CBC/diff and
LFTs -Baseline -Once yearly |
X | X | |||||||||
| Lipid panel -Baseline -Every 6 months |
X | ||||||||||
| Lipid panel -Baseline -4-8 weeks after starting |
X | ||||||||||
| Eye exam -Baseline -Once yearly |
X | ||||||||||
| None required | X |
If patient is on more than one medication, a more restrictive schedule should be used
Include renal function with lab work
Should be rechecked sooner if dose increased
Pregnancy test should be considered before use, and counseling as to use of effective methods of contraception is recommended